Moderate Psoriasis: A Proposed Definition

Actas Dermosifiliogr. 2017 Dec;108(10):911-917. doi: 10.1016/j.ad.2017.07.002. Epub 2017 Aug 17.
[Article in English, Spanish]

Abstract

Introduction: The Psoriasis Area Severity Index (PASI) is the most widely used scale for assessing the severity of psoriasis and for therapeutic decision making. On the basis of the PASI score, patients have been stratified into 2 groups: mild disease and moderate-to-severe disease.

Objective: To draft a proposal for the definition and characterization of moderate psoriasis based on PASI and Dermatology Life Quality Index (DLQI) scores.

Material and methods: A group of 6 dermatologists with experience in the treatment of psoriasis undertook a critical review of the literature and a discussion of cases to draft a proposal.

Results: In order of priority, PASI, DLQI, and body surface area (BSA) are the parameters to be used in daily practice to classify psoriasis as mild, moderate, or severe. Severity should be assessed on the basis of a combined evaluation and interpretation of the PASI and DLQI. And 3, PASI and DLQI should carry equal weight in the determination of disease severity. On this basis, psoriasis severity was defined using the following criteria: mild, PASI<7 and DLQI<7; moderate, PASI=7-15 and DLQI=5-15 (classified as severe when difficult-to-treat sites are affected or when there is a significant psychosocial impact); severe, PASI >15, independently of the DLQI score.

Conclusions: A more precise classification of psoriasis according to disease severity will improve the risk-benefit assessment essential to therapeutic decision making in these patients.

Keywords: Criterio; Criterion; Gravedad; Moderada; Moderada-grave; Moderate; Moderate-to-severe; Psoriasis; Severity.

Publication types

  • Review

MeSH terms

  • Consensus
  • Humans
  • Psoriasis* / classification
  • Psoriasis* / pathology
  • Psoriasis* / psychology
  • Quality of Life
  • Risk Assessment
  • Severity of Illness Index*
  • Surveys and Questionnaires
  • Symptom Assessment